skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer

Abstract

Purpose: Development of new and expensive drugs with activity against pancreatic cancer has made economic considerations more relevant to treatment decision-making for advanced disease. Economic modeling can be used to explore the potential of such novel therapies and to inform clinical trial design. Methods and Materials: We developed a Markov model to evaluate the cost-effectiveness of radiation plus fluorouracil (RT-FU) relative to no treatment in elderly patients with locally advanced pancreatic cancer (LAPC) and to determine the economic potential of radiation plus gemcitabine (RT-GEM), a novel regimen for this disease. We used the SEER-Medicare database to estimate effectiveness and costs supplemented by data from the literature where necessary. Results: Relative to no treatment, RT-FU was associated with a cost-effectiveness ratio (ICER) of $68,724/QALY in the base case analysis. Compared with RT-FU, the ICER for RT-GEM was below $100,000/QALY when the risk of dying with the new regimen was <85% than with the standard regimen. However, >1,000 subjects would be necessary to demonstrate this level of efficacy in a randomized trial. The ICER of RT-GEM was most sensitive to utility values, and, at lower efficacy levels, to costs of gemcitabine and treatment-related toxicity. Conclusions: In elderly patients with LAPC, RT-FU ismore » a cost-effective alternative to no treatment. The novel regimen of RT-GEM is likely to be cost-effective at any clinically meaningful benefit, but quality-of-life issues, drug acquisition, and toxicity-related costs may be relevant, especially at lower efficacy levels.« less

Authors:
 [1];  [2];  [3];  [2]
  1. Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA (United States) and Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario (Canada). E-mail: monika.krzyzanowska@uhn.on.ca
  2. Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA (United States)
  3. Department of Health Policy and Management, Harvard School of Public Health, Boston, MA (United States)
Publication Date:
OSTI Identifier:
20850316
Resource Type:
Journal Article
Resource Relation:
Journal Name: International Journal of Radiation Oncology, Biology and Physics; Journal Volume: 67; Journal Issue: 1; Other Information: DOI: 10.1016/j.ijrobp.2006.07.1390; PII: S0360-3016(06)03002-1; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; CARCINOMAS; CLINICAL TRIALS; COST; DECISION MAKING; DESIGN; DRUGS; ECONOMIC ANALYSIS; HEALTH HAZARDS; MARKOV PROCESS; PANCREAS; PATIENTS; SIMULATION; THERAPY; TOXICITY

Citation Formats

Krzyzanowska, Monika K., Earle, Craig C., Kuntz, Karen M., and Weeks, Jane C. Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer. United States: N. p., 2007. Web. doi:10.1016/j.ijrobp.2006.07.1390.
Krzyzanowska, Monika K., Earle, Craig C., Kuntz, Karen M., & Weeks, Jane C. Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer. United States. doi:10.1016/j.ijrobp.2006.07.1390.
Krzyzanowska, Monika K., Earle, Craig C., Kuntz, Karen M., and Weeks, Jane C. Mon . "Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer". United States. doi:10.1016/j.ijrobp.2006.07.1390.
@article{osti_20850316,
title = {Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer},
author = {Krzyzanowska, Monika K. and Earle, Craig C. and Kuntz, Karen M. and Weeks, Jane C.},
abstractNote = {Purpose: Development of new and expensive drugs with activity against pancreatic cancer has made economic considerations more relevant to treatment decision-making for advanced disease. Economic modeling can be used to explore the potential of such novel therapies and to inform clinical trial design. Methods and Materials: We developed a Markov model to evaluate the cost-effectiveness of radiation plus fluorouracil (RT-FU) relative to no treatment in elderly patients with locally advanced pancreatic cancer (LAPC) and to determine the economic potential of radiation plus gemcitabine (RT-GEM), a novel regimen for this disease. We used the SEER-Medicare database to estimate effectiveness and costs supplemented by data from the literature where necessary. Results: Relative to no treatment, RT-FU was associated with a cost-effectiveness ratio (ICER) of $68,724/QALY in the base case analysis. Compared with RT-FU, the ICER for RT-GEM was below $100,000/QALY when the risk of dying with the new regimen was <85% than with the standard regimen. However, >1,000 subjects would be necessary to demonstrate this level of efficacy in a randomized trial. The ICER of RT-GEM was most sensitive to utility values, and, at lower efficacy levels, to costs of gemcitabine and treatment-related toxicity. Conclusions: In elderly patients with LAPC, RT-FU is a cost-effective alternative to no treatment. The novel regimen of RT-GEM is likely to be cost-effective at any clinically meaningful benefit, but quality-of-life issues, drug acquisition, and toxicity-related costs may be relevant, especially at lower efficacy levels.},
doi = {10.1016/j.ijrobp.2006.07.1390},
journal = {International Journal of Radiation Oncology, Biology and Physics},
number = 1,
volume = 67,
place = {United States},
year = {Mon Jan 01 00:00:00 EST 2007},
month = {Mon Jan 01 00:00:00 EST 2007}
}